Conjunctivitis Treatment Market to Grow with a CAGR of 4.00% through 2028
Increased awareness, product innovation, and regional
variations are expected to drive the Global Conjunctivitis Treatment Market
growth in the forecast period, 2024-2028.
According to TechSci Research report, “Conjunctivitis
Treatment Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Conjunctivitis Treatment Market
stood at USD 4.33 billion in 2022 and is anticipated to grow with a CAGR of 4.00%
in the forecast period, 2024-2028. This can be attributed to awareness and
education. Greater awareness and education about eye health have played a
significant role in boosting the conjunctivitis treatment market. Patients are
now more informed about the symptoms of conjunctivitis and the importance of
seeking prompt medical attention. Public health campaigns, information
dissemination through healthcare providers, and online resources have
contributed to this increased awareness.
Furthermore, the global reach of the conjunctivitis
treatment market is expanding, with pharmaceutical companies focusing on making
their products available in emerging economies. This effort ensures that
individuals in previously underserved regions have access to effective
treatments.
COVID-19 exerted a notable influence on the market's
performance during the pandemic period, primarily due to the potential
emergence of conjunctivitis in individuals infected with the coronavirus.
According to a report by the NCBI published in August 2021, it was observed
that conjunctivitis could manifest in individuals who contracted COVID-19. This
increased focus on conjunctivitis during the pandemic had the potential to
boost market demand. However, the easing of stringent lockdown measures is anticipated
to result in a higher influx of patients seeking treatment for conjunctivitis,
thereby fostering the growth of the market over the next five years.
The market, in its forecasted period, is poised for
growth due to the substantial number of individuals affected by conjunctivitis
and the widespread availability of treatment options worldwide. As outlined in
an NCBI article from April 2021, allergic conjunctivitis ranked as one of the
most prevalent ocular disorders among participants, with a prevalence rate of
1.3%. Given its widespread occurrence, treatment options are readily
accessible.
In most cases, conjunctivitis can be self-diagnosed,
minimizing the necessity for diagnostic tests. Consequently, the prevalence of
allergic conjunctivitis is anticipated to be a significant driver of market
growth during the forecasted period. Additionally, according to an NIH article
from February 2021, viral and bacterial conjunctivitis represent the two common
forms of infectious conjunctivitis, with viral infections accounting for up to
80% of acute conjunctivitis cases and bacterial infections responsible for
between 50-75% of cases in children. The prevalence of conjunctivitis is also
substantial in countries like China, as indicated by a BMC article published in
March 2022, which reported an average annual incidence of hemorrhagic
conjunctivitis at 3.58 per 100,000 individuals in mainland China. The
increasing incidence of hemorrhagic conjunctivitis is expected to spur demand
for conjunctivitis treatment, further contributing to market growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Conjunctivitis Treatment Market.”
The Global Conjunctivitis Treatment Market is
segmented into disease type, formulation type, regional distribution, and
company.
Based on its disease type, Allergic conjunctivitis is
poised to capture a substantial portion of the market. It is a common condition
characterized by sudden eyelid swelling and eye itching, particularly prevalent
among individuals with allergies.
A Nature article from April 2022 reported that roughly
10% of the sample population experienced allergic conjunctivitis. In India,
among individuals aged five to 15 years, the prevalence of allergic
conjunctivitis stood at 12.22%. Furthermore, according to an NCBI article
published in January 2021, over half of the patients reported daily symptoms,
whether seasonal or perennial, with approximately 75% classifying their
symptoms as severe. The same source also noted an incidence rate of vernal
keratoconjunctivitis ranging from 1.2 to 10.6 cases per 10,000 individuals in
Europe. These statistics suggest a significant demand for effective treatment,
contributing to the growth of this particular market segment.
Based on formulation type, Drops are poised to
dominate the Global Conjunctivitis Treatment Market for several compelling
reasons. First and foremost, drops offer a convenient and user-friendly mode of
administration, making them highly accessible to a broad patient base. Additionally,
drops provide targeted and localized treatment directly to the affected area,
ensuring effective symptom relief. Furthermore, the versatility of drops allows
for a range of formulations, including anti-inflammatory and anti-allergy
variants, catering to the diverse needs of conjunctivitis patients. As
consumers increasingly seek non-invasive and quick-acting solutions, drops
align perfectly with these preferences, positioning them as the preferred
choice in the conjunctivitis treatment landscape. Their widespread
availability, ease of use, and effectiveness are key factors driving their
dominance in this market.
Major companies operating in Global Conjunctivitis
Treatment Market are:
- Novartis AG
- Bausch & Lomb Inc
- Allergan UnLtd Co
- Nicox S.A.
- Alembic Pharmaceuticals Ltd
- Sanofi SA
- Pfizer Inc
- Sirion Therapeutics Inc
- SANTEN PHARMACEUTICAL CO., LTD.
- Auven Therapeutics Management LLLP
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global Conjunctivitis Treatment Market is poised
for innovation and growth, driven by emerging trends such as biologics,
personalized medicine, telemedicine, nanotechnology, and regenerative
therapies. These trends aim to improve treatment effectiveness, patient
experience, and accessibility. As the market continues to evolve, healthcare
providers, pharmaceutical companies, and researchers must stay abreast of these
developments to provide the best possible care to individuals suffering from
conjunctivitis. The future holds exciting possibilities for more effective and
patient-centric conjunctivitis treatments,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Conjunctivitis Treatment Market By
Disease Type (Allergic Conjunctivitis, Bacterial
Conjunctivitis, Viral Conjunctivitis), By Formulation Type (Ointment, Drops,
Drugs), By
Region, By Competition Forecast
& Opportunities, 2018-2028F”, has evaluated the future growth potential of Global
Conjunctivitis Treatment Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Conjunctivitis
Treatment Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States-
10170
Tel: +13322586602
Email: [email protected]
Website: www.techsciresearch.com